One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target

Journal of Diabetes and its Complications

Volumn 27, Issue 5, 2013, Pages 492-500

  Rosenstock, Julio ^a   Rodbard, Helena W ^b   Bain, Stephen C ^c   D'Alessio, David ^d   Seufert, Jochen ^e   Thomsen, Anne B ^f   Svendsen, Claus Bo ^f   Devries, J Hans ^g  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Endocrine and Metabolic Consultants   (United States)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Insulin detemir; Liraglutide; Treatment intensification; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL LIPASE;

ANTIBODY RESPONSE; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSS REACTION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG FATALITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OROPHARYNX PAIN; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

INSULIN DETEMIR; LIRAGLUTIDE; TREATMENT INTENSIFICATION; TYPE 2 DIABETES;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; WEIGHT LOSS;

EID: 84883778164     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2013.04.008     Document Type: Article

References (27)

1. S. Arnolds, S. Dellweg, J. Clair, M.P. Dain, M.A. Nauck, and K. Rave Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study Diabetes Care 33 2010 1509 1515
2. S.C. Bain, J. Seufert, A.B. Thomsen, S. Furber, and D. D'Alessio Liraglutide + metformin in type 2 diabetes: clinical benefits associated with switch or use early in the disease process Diabetes 61 Suppl 1 2010 A301 (abstract 1168-P)
3. P.A. Banks, T.L. Bollen, C. Dervenis, H.G. Gooszen, C.D. Johnson, and M.G. Sarr Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus Gut 62 2013 102 111
4. P.C. Bartley, M. Bogoev, J. Larsen, and A. Philotheou Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial Diabetic Medicine 25 2008 442 449
5. J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, and A.Y. Kwan Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Annals of Internal Medicine 154 2011 103 112
6. J.B. Buse, A. Garber, J. Rosenstock, W.E. Schmidt, J.H. Brett, and N. Videbæk Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials Journal of Clinical Endocrinology and Metabolism 96 2011 1695 1702
7. ClinicalTrials.gov Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results - a long term evaluation (LEADER®) (NCT01179048) 2012 Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01179048 (accessed December 18, 2012).
8. ClinicalTrials.gov Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes (NCT01144338) 2012 Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338 (accessed December 18, 2012).
9. ClinicalTrials.gov The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes (NCT01617434) 2012 Available from: http://clinicaltrials.gov/ct2/show/ NCT01617434 (accessed December 18, 2012).
10. J.H. DeVries, S.C. Bain, H.W. Rodbard, J. Seufert, D. D'Alessio, and A.B. Thomsen Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets Diabetes Care 35 2012 1446 1454
11. K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P.A. Home 26-week, randomized, parallel, treat-to target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naïve people with type 2 diabetes Diabetes Care 29 2006 1269 1274
12. P. Hollander, K. Raslova, T.V. Skjoth, J. Rastam, and J.F. Liutkus Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial Diabetes, Obesity & Metabolism 13 2011 268 275
13. P.F. Hsu, S.H. Sung, H.M. Cheng, J.S. Yeh, W.L. Liu, and W.L. Chan Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes mellitus: a nationwide population-based study Diabetes Care 36 2012 894 900
14. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
15. U. Kielgast, M. Asmar, S. Madsbad, and J.J. Holst Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients Journal of Clinical Endocrinology and Metabolism 95 2010 2492 2496
16. M. Nauck, A. Frid, K. Hermansen, A.B. Thomsen, M. During, and N. Shah Long-term efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study Diabetes, Obesity & Metabolism 15 2012 204 212
17. M.A. Nauck, M.M. Heimesaat, K. Behle, J.J. Holst, M.S. Nauck, and R. Ritzel Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers Journal of Clinical Endocrinology and Metabolism 87 2002 1239 1246
18. R.A. Noel, D.K. Braun, R.E. Patterson, and G.L. Bloomgren Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 32 2009 834 838
19. M. Peyrot, R.R. Rubin, and K. Khunti Addressing barriers to initiation of insulin in patients with type 2 diabetes Primary Care Diabetes 4 Suppl 1 2010 S11 S18
20. R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, and S. Filetti One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial International Journal of Clinical Practice 65 2011 397 407
21. M.C. Riddle, J. Rosenstock, J. Gerich, and Insulin Glargine 4002 Study Investigators The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086
22. H.W. Rodbard, P.S. Jellinger, J.A. Davidson, D. Einhorn, A.J. Garber, and G. Grunberger Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocrine Practice 15 2009 540 559
23. W. Steinberg, J.H. DeVries, T. Wadden, C.B. Jensen, C.B. Svendsen, and J. Rosenstock Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide Gastroenterology 142 Suppl 1 2012 S850 S851
24. S.G. Swinnen, M.P. Dain, D. Mauricio, J.H. DeVries, J.B. Hoekstra, and F. Holleman Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes Diabetes, Obesity & Metabolism 12 2010 923 925
25. US Food and Drug Administration Information for healthcare professionals - exenatide (marketed as Byetta) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm 2008 (accessed December 18, 2012).
26. US Food and Drug Administration Information for healthcare professionals - acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm 2009 (accessed December 18, 2012).
27. Y. Zhao, C.R. Campbell, V. Fonseca, and L. Shi Impact of hypoglycaemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes Diabetes Care 35 2012 1126 1132